Abstract IA006: Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer
Authors: Wyatt Alexander W. , Murtha Andrew J. , Warner Evan , Van der Eecken Kim , Kwan Edmond M. , Herberts Cameron , Sipola Joonatan , Ng Sarah W.S. , Chen Xinyi E. , Fonseca Nicolette M. , Ritch Elie , Schönlau Elena , Bernales Cecily Q. , Donnellan Gráinne , Beja Kevin , Wong Amanda , Verbeke Sofie , Lumen Nicolaas , Van Dorpe Jo , De Laere Bram , Annala Matti , Vandekerkhove Gillian , Ost Piet 
Published: June 2023

Background: De novo metastatic castration-sensitive prostate cancer (mCSPC) is highly aggressive, but the lack of routine tumor tissue in this setting hinders genomic stratification and jeopardizes precision oncology efforts. Accurate molecular profiling at diagnosis is important for future genomics-informed risk stratification strategies and biomarker-guided treatment. Currently, it is unclear the extent that intrapatient tumor heterogeneity impacts clinical cancer genotyping. Methods: We performed genomic profiling of 607 synchronous primary foci, metastatic lesions, and plasma cell-free DNA from a rare clinical trial cohort of 43 patients with de novo mCSPC who underwent radical prostatectomy at diagnosis. Surgery is not currently standard practice in this disease setting. All samples were subjected to targeted DNA sequencing using a bespoke prostate cancer-specific panel and a subset were also subjected to whole-exome sequencing. Results: Sequencing-derived tissue tumor fraction was highly heterogeneous between samples, and was below 40% across all foci in approximately 20% of patients, potentially precluding routine detection of key classes of clinically-relevant biomarkers. In samples with high tumor fraction, the genomic landscape of mCSPC closely resembled metastatic castration-resistant prostate cancer. In same-patient samples, intra-prostate heterogeneity in mutation, copy number, and whole-genome duplication was pervasive and affected tumor suppressor genes including PTEN, TP53, and RB1. Phylogenetic modeling demonstrated additional complexity in several patients driven by polyclonal metastatic seeding from the reservoir of primary populations. While the metastatic clones were often identified in the primary site, frequent discordance between select primary foci and synchronous metastases in clinically-relevant genes, plus highly variable per-sample tumor fraction, resulted in false genotyping of the dominant disease, when relying on a single tissue focus. However, in silico modeling demonstrated that analysis of multiple prostate diagnostic biopsy cores can rescue misassigned somatic genotypes. Conclusions: Our work reveals extensive polyclonality that undermines standard precision genotyping in de novo mCSPC, nominates practical strategies for improved biomarker profiling and genomics-informed risk stratification and offers deep biological insight into the relationship between primary and untreated metastases.

Citation Format: Alexander W. Wyatt, Andrew J. Murtha, Evan Warner, Kim Van der Eecken, Edmond M. Kwan, Cameron Herberts, Joonatan Sipola, Sarah W.S. Ng, Xinyi E. Chen, Nicolette M. Fonseca, Elie Ritch, Elena Schönlau, Cecily Q. Bernales, Gráinne Donnellan, Kevin Beja, Amanda Wong, Sofie Verbeke, Nicolaas Lumen, Jo Van Dorpe, Bram De Laere, Matti Annala, Gillian Vandekerkhove, Piet Ost. Overcoming complex polyclonality for accurate clinical genotyping in metastatic prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Advances in Prostate Cancer Research; 2023 Mar 15-18; Denver, Colorado. Philadelphia (PA): AACR; Cancer Res 2023;83(11 Suppl):Abstract nr IA006.